FindTrial
Sign In

clopidgorel pharmacogenetics study in normal healthy volunteers

Association of genetic polymorphisms of Cytochrome P450 2C19, ABCB1, P2Y12, Prakriti and response to clopidogrel in normal healthy participants

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/06/001795
Enrollment
100
Registered
2011-06-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Clopidogrel: Single dose of 300 mg tablet clopidogrel No comparator Intervention2: Clopidogrel 300 mg: Single dose of 300 mg tablet clopidogrel. No comparator agent Intervention3: Clopi

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Normal healthy as adjudged by medical history physical examination hematological biochemical and urine analysis with platelet aggregation at the baseline at least 70 percentage

Exclusion criteria

Exclusion criteria: Unwilling to participate in the study

Design outcomes

Primary

MeasureTime frame
Percentage reduction in the inhibition of platelet aggregation (Between pre dose and 4 hours post dose)Timepoint: 0hr and 4 hrs—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactUrmila Thatte

Seth GS Medical College and KEM Hospital

urmilathatte@gmail.com022-24133767

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026